Camera-facing image of MAVENCLAD patient Vickie with headline "Are you ready?"

ARE YOU
READY?

VICKIE, MAVENCLAD PATIENT, DOSED IN 2019 AND 2021

MAVENCLAD is a relapsing MS treatment that’s
not an infusion, not an injection, not a daily pill.*

*Not taken every day of the year.

MAVENCLAD is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, MAVENCLAD is generally used in people who have tried another MS medicine that they could not tolerate or that has not worked well enough.

MAVENCLAD is not recommended for use in people with clinically isolated syndrome (CIS).

Tap each topic below to discover more about MAVENCLAD.

PROVEN RESULTS

Explore our results in a 96-week clinical trial, where MAVENCLAD was proven to reduce the rate of relapses, significantly decrease the development of new and active lesions, and reduce disability progression

PROVEN TO REDUCE RELAPSES BY OVER HALF AND SLOW DISABILITY PROGRESSION

MAVENCLAD was studied in RMS patients to measure how well it works (efficacy) and to evaluate its safety. The trial compared MAVENCLAD to placebo at 96 weeks in these 3 ways.

Learn more about this data and the efficacy of MAVENCLAD at MAVENCLAD.com or sign up for more info below.

†Rate of relapses: MAVENCLAD 0.14 vs placebo 0.33.
‡Mean number of lesions: MAVENCLAD 0.38 vs placebo 1.43. Median number of lesions: MAVENCLAD 0 vs placebo 0.67. The mean relative reduction reflects that not all patients had lesions.
§Disability progression: MAVENCLAD 13% vs placebo 19% with 3-month confirmed EDSS progression. This analysis was not adjusted to account for the number of analyses performed and should be considered exploratory.

CONVENIENT, ORAL DOSING

Get to know the MAVENCLAD convenient dosing schedule, with no more than 10 treatment days a year for 2 years

10
oral treatment days a year for 2 years
NO MORE THAN

MAVENCLAD is the first and only short-course oral therapy with no more than 10 treatment days a year for 2 years.*

Each week of MAVENCLAD treatment is known as a cycle and consists of 1 or 2 MAVENCLAD pills a day for 4 or 5 days (depending on your body weight) in a row. There are two MAVENCLAD cycles a year, about a month apart, over 2 years. Dosing depends on your weight.

Learn more about convenient dosing at MAVENCLAD.com or sign up for more info below.

*Your healthcare provider will continue to monitor your health during the 2 yearly treatment courses, as well as between treatment courses and for at least another 2 years, during which you do not need to take MAVENCLAD. Your healthcare provider may delay or completely stop treatment with MAVENCLAD if you have severe side effects. It is not known if it is safe and effective for people to restart MAVENCLAD after the full 4-year period.

WELL-ESTABLISHED SAFETY PROFILE

Learn about our safety profile, which has more than 17 years of evaluation in clinical trials, follow-up, and real-world experience

MAVENCLAD safety profile has been evaluated for
17+
YEARS

When it comes to choosing an RMS treatment, safety is a key factor. That’s why MAVENCLAD has been evaluated in clinical trials, follow-up, and real-world experience.*

MAVENCLAD continues to be evaluated, today and beyond.

In the real-world setting, 56,000 PEOPLE have been treated globally with MAVENCLAD

Learn more about the MAVENCLAD safety profile at MAVENCLAD.com or sign up for more info below.

MAVENCLAD may cause serious side effects.

Treatment with MAVENCLAD may increase your risk of developing cancer. You should follow healthcare provider instructions about screening for cancer. Because of the risk of birth defects, do not take MAVENCLAD if you are pregnant or of childbearing potential and not using effective birth control.

These are not all of the side effects associated with MAVENCLAD. Please see full Prescribing Information/Medication Guide, including serious side effects, for additional Important Safety Information.

*It is not known if MAVENCLAD is safe and effective for people to restart MAVENCLAD treatment 2 years after completing their 2 yearly treatment courses.

PATIENT & FINANCIAL SUPPORT PROGRAMS

Discover the many ways MAVENCLAD offers support throughout your treatment journey with MS LifeLines®, including our co-pay* options, financial support specialists, and MS-certified nurses

Financial assistance for eligible patients

Co-pay for eligible* patients

If you have insurance and are eligible, you could pay as little as $0 co-pay or co-insurance for MAVENCLAD. MS LifeLines® also offers other assistance programs, including free medication, to help eligible patients gain access to MAVENCLAD.

*Some limitations are required by law. Patients covered by federal or state healthcare programs, including Medicare and Medicaid, are not eligible for assistance. This program is open to residents of the U.S. and Puerto Rico with relapsing forms of multiple sclerosis who are starting MAVENCLAD therapy or presently taking MAVENCLAD.

MS LifeLines® financial support specialists can help you:

  • Verify your insurance benefits to determine coverage and navigate how much you may have to pay for medication (out of-pocket expenses)
  • Learn about MS LifeLines® financial assistance options and determine if you qualify
  • Work with specialty pharmacies to facilitate treatment and help coordinate treatment delivery

MS LifeLines® Nurses are there for you

MS LifeLines® nurses can:

  • Help you with treatment throughout your 2 years on MAVENCLAD
  • Send you treatment reminders via email or text
  • Provide MS education tips to help manage certain symptoms
GET SUPPORT

EDUCATIONAL EVENTS

Learn about MAVENCLAD treatment from a healthcare professional at the next in-person or virtual event

Looking to learn more about MAVENCLAD from HCPs?

In these presentations, led by a healthcare provider (HCP), you will learn about MAVENCLAD, an oral treatment option for relapsing MS with a unique dosing schedule. A healthcare provider will review how MAVENCLAD is thought to work as well as its efficacy, safety profile, and dosing schedule. You will also learn about live and non-live vaccines, how they work, and get information about vaccinations for patients considering MAVENCLAD.

FREE INFO KIT

Get more info about all MAVENCLAD can offer

Have the facts about MAVENCLAD sent straight to you with the MAVENCLAD Info Kit, which includes information about:

  • MAVENCLAD dosing schedule
  • How MAVENCLAD is thought to work
  • What to expect with treatment
  • Safety profile and side effects
  • Support through MS LifeLines®

Important Safety Information

MAVENCLAD may cause serious side effects, including:
  • Risk of cancer (malignancies). You should follow healthcare provider instructions about screening for cancer.
  • MAVENCLAD may cause birth defects if used during pregnancy. Women must not be pregnant when they start treatment with MAVENCLAD or become pregnant during MAVENCLAD dosing and within 6 months after the last dose of each yearly treatment course. You should stop treatment with MAVENCLAD and contact your healthcare provider right away if you become pregnant during treatment with MAVENCLAD.
    • For women who are able to become pregnant:
      • Your healthcare provider should order a pregnancy test before you begin your first and second yearly treatment course of MAVENCLAD to make sure that you are not pregnant.
    • Ask your healthcare provider which contraceptive method is right for you. Women and men being treated with MAVENCLAD should use effective birth control (contraception) on the days on which they take MAVENCLAD and for at least 6 months after the last dose of each yearly treatment course.
Do not take MAVENCLAD if you:
  • have cancer (malignancy).
  • are pregnant, plan to become pregnant, or are a woman of childbearing age or a man able to father a child and you are not using birth control.
  • are breastfeeding.
  • are human immunodeficiency virus (HIV) positive.
  • have active infections, including tuberculosis (TB), hepatitis B or C.
  • are allergic to cladribine.
Before you take MAVENCLAD, tell your healthcare provider about all of your medical conditions, including if you:
  • think you have an infection.
  • have taken, take, or plan to take medicines that affect your immune system or blood cells, or other treatments for MS. Certain medicines can increase your risk of getting an infection.
  • have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive live or live-attenuated vaccines within the 4 to 6 weeks preceding treatment with MAVENCLAD or receive these types of vaccines during your treatment with MAVENCLAD and unless directed by your healthcare provider.
  • have heart failure.
  • have or have had cancer.
  • have liver or kidney problems.
  • are breastfeeding or plan to breastfeed. It is not known if MAVENCLAD passes into your breast milk. Do not breastfeed on the days on which you take MAVENCLAD, and for 10 days after the last dose.
How should I take MAVENCLAD?
  • MAVENCLAD is given as two yearly treatment courses, consisting of 2 treatment weeks (cycles) about a month apart.
  • Handle MAVENCLAD with dry hands and take immediately after opening the blister pack. Take with water and do not chew the tablet. MAVENCLAD can be taken with or without food and should be taken at least 3 hours apart from other medicines.
  • Wash your hands after handling MAVENCLAD. Limit contact with your skin (especially on your face). Wash skin and surfaces with water if contact occurs.
  • If you miss a dose, take it as soon as you remember on the same day. If the whole day passes before you remember, take your missed dose the next day. Do not take 2 doses at the same time. Instead, you will extend the number of days in that treatment week.

Your healthcare provider will continue to monitor your health during the 2 yearly treatment courses, and for at least another 2 years during which you do not need to take MAVENCLAD. It is not known if MAVENCLAD is safe and effective in people who restart MAVENCLAD treatment more than 2 years after completing 2 yearly treatment courses.

MAVENCLAD can cause serious side effects. If you have any of these symptoms listed below, call your healthcare provider right away:
  • low blood cell counts have happened and can increase your risk of infections during treatment with MAVENCLAD. Blood tests are needed before you start treatment with MAVENCLAD, during your treatment with MAVENCLAD, and afterward, as needed.
  • serious infections such as:
    • life-threatening or fatal infections caused by bacteria, viruses, parasites or fungi.
    • TB, hepatitis B or C, and shingles (herpes zoster). Fatal cases of TB and hepatitis have happened with cladribine during clinical studies. Tell your healthcare provider right away if you get any symptoms of the following infection related problems or if any of the symptoms get worse, including fever, aching painful muscles, headache, feeling of being generally unwell, loss of appetite, burning, tingling, numbness or itchiness of the skin in the affected area, skin blotches, blistered rash, or severe pain.
    • progressive multifocal leukoencephalopathy (PML). PML is a rare brain infection that usually leads to death or severe disability. Although PML has not been seen in MS patients taking MAVENCLAD, it may happen in people with weakened immune systems. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These may include: weakness on 1 side of your body, loss of coordination in your arms and legs, decreased strength, problems with balance, changes in your vision, changes in your thinking or memory, confusion, or changes in your personality.
  • liver problems. Blood tests should be performed to check your liver before you start taking MAVENCLAD. Symptoms of liver problems may include: nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or your skin or the whites of your eyes turn yellow.
  • allergic reactions (hypersensitivities). You should stop treatment and seek immediate medical attention if any signs or symptoms of allergic reactions occur. Symptoms of an allergic reaction may include skin rash, swelling or itching of the face, lips, tongue or throat, or trouble breathing.
  • heart failure. MAVENCLAD may cause heart failure, which means your heart may not pump as well as it should. Call your healthcare provider or go to the closest emergency room for medical help right away if you have any signs or symptoms such as shortness of breath, a fast or irregular heart beat, or unusual swelling in your body.

The most common side effects of MAVENCLAD include: upper respiratory infection, headache, and low white blood cell counts.

These are not all the possible side effects of MAVENCLAD. Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact EMD Serono at: 1-800-283-8088 ext. 5563 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information/Medication Guide, including serious side effects, for additional Important Safety Information.

EMD Serono logo

US-MAV-01820
Last update 04/2024

Certain images show people living with MS who were considered MAVENCLAD patients as of 03/24.

©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

MAVENCLAD and MS LIfeLines are registered trademarks of Merck KGAA, Darmstadt, Germany or its affiliates.

EMD Serono, Inc., One Technology Place, Rockland, MA 02370

This website is intended for residents of the United States.

Use and access of this site are subject to the terms and conditions set out in our Terms & Conditions and Privacy Policy.

PRIVACY POLICY

CONSUMER HEALTH DATA PRIVACY POLICY

TERMS & CONDITIONS

COOKIE SETTINGS

Important Safety Information
Expand
MAVENCLAD may cause serious side effects, including:
  • Risk of cancer (malignancies). You should follow healthcare provider instructions about screening for cancer.
  • MAVENCLAD may cause birth defects if used during pregnancy. Women must not be pregnant when they start treatment with MAVENCLAD or become pregnant during MAVENCLAD dosing and within 6 months after the last dose of each yearly treatment course. You should stop treatment with MAVENCLAD and contact your healthcare provider right away if you become pregnant during treatment with MAVENCLAD.
    • For women who are able to become pregnant:
      • Your healthcare provider should order a pregnancy test before you begin your first and second yearly treatment course of MAVENCLAD to make sure that you are not pregnant.
    • Ask your healthcare provider which contraceptive method is right for you. Women and men being treated with MAVENCLAD should use effective birth control (contraception) on the days on which they take MAVENCLAD and for at least 6 months after the last dose of each yearly treatment course.
Do not take MAVENCLAD if you:
  • have cancer (malignancy).
  • are pregnant, plan to become pregnant, or are a woman of childbearing age or a man able to father a child and you are not using birth control.
  • are breastfeeding.
  • are human immunodeficiency virus (HIV) positive.
  • have active infections, including tuberculosis (TB), hepatitis B or C.
  • are allergic to cladribine.
Before you take MAVENCLAD, tell your healthcare provider about all of your medical conditions, including if you:
  • think you have an infection.
  • have taken, take, or plan to take medicines that affect your immune system or blood cells, or other treatments for MS. Certain medicines can increase your risk of getting an infection.
  • have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive live or live-attenuated vaccines within the 4 to 6 weeks preceding treatment with MAVENCLAD or receive these types of vaccines during your treatment with MAVENCLAD and unless directed by your healthcare provider.
  • have heart failure.
  • have or have had cancer.
  • have liver or kidney problems.
  • are breastfeeding or plan to breastfeed. It is not known if MAVENCLAD passes into your breast milk. Do not breastfeed on the days on which you take MAVENCLAD, and for 10 days after the last dose.
How should I take MAVENCLAD?
  • MAVENCLAD is given as two yearly treatment courses, consisting of 2 treatment weeks (cycles) about a month apart.
  • Handle MAVENCLAD with dry hands and take immediately after opening the blister pack. Take with water and do not chew the tablet. MAVENCLAD can be taken with or without food and should be taken at least 3 hours apart from other medicines.
  • Wash your hands after handling MAVENCLAD. Limit contact with your skin (especially on your face). Wash skin and surfaces with water if contact occurs.
  • If you miss a dose, take it as soon as you remember on the same day. If the whole day passes before you remember, take your missed dose the next day. Do not take 2 doses at the same time. Instead, you will extend the number of days in that treatment week.

Your healthcare provider will continue to monitor your health during the 2 yearly treatment courses, and for at least another 2 years during which you do not need to take MAVENCLAD. It is not known if MAVENCLAD is safe and effective in people who restart MAVENCLAD treatment more than 2 years after completing 2 yearly treatment courses.

MAVENCLAD can cause serious side effects. If you have any of these symptoms listed below, call your healthcare provider right away:
  • low blood cell counts have happened and can increase your risk of infections during treatment with MAVENCLAD. Blood tests are needed before you start treatment with MAVENCLAD, during your treatment with MAVENCLAD, and afterward, as needed.
  • serious infections such as:
    • life-threatening or fatal infections caused by bacteria, viruses, parasites or fungi.
    • TB, hepatitis B or C, and shingles (herpes zoster). Fatal cases of TB and hepatitis have happened with cladribine during clinical studies. Tell your healthcare provider right away if you get any symptoms of the following infection related problems or if any of the symptoms get worse, including fever, aching painful muscles, headache, feeling of being generally unwell, loss of appetite, burning, tingling, numbness or itchiness of the skin in the affected area, skin blotches, blistered rash, or severe pain.
    • progressive multifocal leukoencephalopathy (PML). PML is a rare brain infection that usually leads to death or severe disability. Although PML has not been seen in MS patients taking MAVENCLAD, it may happen in people with weakened immune systems. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These may include: weakness on 1 side of your body, loss of coordination in your arms and legs, decreased strength, problems with balance, changes in your vision, changes in your thinking or memory, confusion, or changes in your personality.
  • liver problems. Blood tests should be performed to check your liver before you start taking MAVENCLAD. Symptoms of liver problems may include: nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or your skin or the whites of your eyes turn yellow.
  • allergic reactions (hypersensitivities). You should stop treatment and seek immediate medical attention if any signs or symptoms of allergic reactions occur. Symptoms of an allergic reaction may include skin rash, swelling or itching of the face, lips, tongue or throat, or trouble breathing.
  • heart failure. MAVENCLAD may cause heart failure, which means your heart may not pump as well as it should. Call your healthcare provider or go to the closest emergency room for medical help right away if you have any signs or symptoms such as shortness of breath, a fast or irregular heart beat, or unusual swelling in your body.

The most common side effects of MAVENCLAD include: upper respiratory infection, headache, and low white blood cell counts.

These are not all the possible side effects of MAVENCLAD. Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact EMD Serono at: 1-800-283-8088 ext. 5563 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information/Medication Guide, including serious side effects, for additional Important Safety Information.